Bhatt DL, Eagle KA, Ohman EM, et al. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA.2010;304:1350-1357. Available at: https://www.ncbi.nlm.nih.gov/pubmed/20805624 Last accessed June 2018
Yusuf S, Hawken S, Ôunpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937-952.
Sabatine, M. S. et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N. Engl. J. Med. 376, 1713–1722 (2017).
Sampson UK. et al. Residual Cardiovascular Risk Despite Optimal LDL-Cholesterol Reduction with Statins: The Evidence, Etiology, and Therapeutic Challenges. NIH. 14(1): 1–10. doi:10.1007/s11883-011-0219-7. (2012).
Wong ND, et al. Prevalence of the American College of Cardiology/American Heart Association statin eligibility groups, statin use, and low-density lipoprotein cholesterol control in US adults using the National Health and Nutrition Examination Survey 2011–2012. Journal of Clinical Lipidology 10, 1109–1118. (2016).